Company Filing History:
2 out of 1,746 
2 out of 90 
Years Active: 2013-2015
Title: Innovations by Eric Chojnicki in CNS Remyelination
Introduction
Eric Chojnicki is an accomplished inventor based in Houston, TX, who has made significant contributions to the field of medical science. He holds 2 patents that focus on innovative treatments for demyelinating diseases and other central nervous system disorders. His work is particularly relevant in the context of neural dysfunction caused by spinal cord injuries.
Latest Patents
Chojnicki's latest patents include compositions and methods that utilize a recombinant human monoclonal antibody (MAB) aimed at promoting central nervous system (CNS) remyelination. These antibodies demonstrate activity in treating demyelinating diseases and other CNS disorders of viral, bacterial, or idiopathic origin. The patents describe neuromodulatory agents that consist of antibodies capable of binding to structures or cells in the CNS, as well as peptide analogs, haptens, and their active fragments. The methods outlined in his patents involve the use of polyclonal IgM antibodies and various human monoclonal antibodies, which can be administered in low doses to effectively treat conditions involving demyelination and promote remyelination.
Career Highlights
Throughout his career, Eric Chojnicki has worked with notable organizations such as the Mayo Foundation for Medical Education and Research and Acorda Therapeutics, Inc. His experience in these institutions has allowed him to develop and refine his innovative approaches to treating CNS disorders.
Collaborations
Chojnicki has collaborated with esteemed colleagues, including Elliot A Gruskin and Arthur E Warrington, to advance research in the field of CNS remyelination. Their combined expertise has contributed to the development of effective therapeutic applications.
Conclusion
Eric Chojnicki's contributions to the field of CNS remyelination through his innovative patents and collaborations highlight the importance of research in developing effective treatments for demyelinating diseases. His work continues to pave the way for advancements in medical science.